• Chairman Mr. Alan Tribe appointed as new Managing Director
• Dr. Rohan Hockings resigns as CEO and Executive Director
• No changes to Mr. Tribe's current terms of engagement or remuneration

PYC Therapeutics Limited (ASX:PYC) has announced the appointment of Chairman Mr. Alan Tribe as the Company's new Managing Director, effective immediately. This follows the resignation of Dr. Rohan Hockings as Chief Executive Officer and Executive Director, who will be leaving the Company by 16 November 2025 after a 2-month notice period. Since joining the Board in 2018, Mr. Tribe has brought his extensive corporate and commercial experience to the Company and has worked closely with the executive management team. He is well-versed in the Company's operations and will now be based in the Perth office on a full-time basis. There will be no changes to his current terms of engagement or remuneration. As Managing Director, Mr. Tribe will also assume responsibility for the Company's Investor Relations and Business Development activities. The Company will commence a search for a permanent Managing Director to lead the future growth and development of the business for its shareholders. The Polycystic Kidney Disease programme remains a priority, and updates will continue to be provided on progress towards the milestones previously advised.